Advertisement

Hormones

, Volume 15, Issue 1, pp 122–128 | Cite as

TSH-secreting pituitary adenomas treated by gamma knife radiosurgery: our case experience and a review of the literature

  • Zadalla Mouslech
  • Maria Somali
  • Anastasia Konstantina Sakali
  • Christos Savopoulos
  • George Mastorakos
  • Apostolos I. Hatzitolios
Case report
  • 2 Downloads

Abstract

A 43-year-old woman, previously misdiagnosed as having primary hyperthyroidism and treated with antithyroid drugs, presented to us with overt hyperthyroidism, high levels of thyroid hormones and elevated thyroid-stimulating hormone (TSH). Magnetic resonance imaging (MRI) revealed a pituitary microadenoma extending suprasellarly. The patient responded favorably to initial treatment with somatostatin analogs for 2 years but due to the escape phenomenon, TSH levels escalated and hyperthyroidism relapsed. Transsphenoidal adenomectomy was applied but recurrence was again observed due to incomplete tumor removal. Gamma knife radiosurgery was finally employed 5.5 years ago, resulting in complete disease remission without evidence of long-term complications to date. Thyrotropin-secreting adenomas (TSHomas) are rare with an estimated prevalence of about one case per million. We retrieved from the literature 14 cases of TSHomas treated by gamma knife radiosurgery and compared the outcomes. Our results demonstrate the efficacy and safety of gamma knife radiosurgery for achieving remission in most of the cases, suggesting validation of this technique as an effective treatment option for the management of recurrent TSHomas.

Key words

Thyrotropin-secreting pituitary adenoma Hyperthyroidism Long-acting somatostatin analogs Transsphenoidal adenomectomy Gamma knife radiosurgery Long-term remission 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mindermann T, Wilson CB, 1993 Thyrotropin-producing pituitary adenomas. J Neurosurg 79: 521–527.CrossRefPubMedGoogle Scholar
  2. 2.
    Önnestam L, Berinder K, Burman P, et al, 2013 National Incidence and Prevalence of TSH-Secreting Pituitary Adenomas in Sweden. J Clin Endocrinol Metab 98: 626–635.CrossRefPubMedGoogle Scholar
  3. 3.
    Raappana A, Koivukangas J, Ebeling T, Pirilä T, 2010 Incidence of pituitary adenomas in Northern Finland in 1992–2007. J Clin Endocrinol Metab 95: 4268–4275.CrossRefPubMedGoogle Scholar
  4. 4.
    Gruppetta M, Mercieca C, Vassallo J, 2013 Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16: 545–553.CrossRefPubMedGoogle Scholar
  5. 5.
    Jailer JW, Holub DA, 1960 Remission of Graves’ disease following radiotherapy of a pituitary neoplasm. Am J Med 28: 497–500.CrossRefPubMedGoogle Scholar
  6. 6.
    Beck-Peccoz P, Persani L, Lania A 2015 Thyrotropin-Secreting Pituitary Adenomas. In: De Groot LJ, Beck-Peccoz P, Chrousos G et al, (eds) Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; Available at: http://www.ncbi.nlm.nih.gov/books/NBK278978/Google Scholar
  7. 7.
    Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD, 1999 Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes Of Health. J Clin Endocrinol Metab 84: 476–486.CrossRefPubMedGoogle Scholar
  8. 8.
    Losa M, Mortini P, Franzin A, Barzaghi R, Mandelli C, Giovanelli M, 1999 Surgical management of thyrotropin-secreting pituitary adenomas. Pituitary 2: 127–131.CrossRefPubMedGoogle Scholar
  9. 9.
    Socin H, Chanson P, Delemer B, et al, 2003 The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 148: 433–442.CrossRefPubMedGoogle Scholar
  10. 10.
    Van Varsseveld NC, Bisschop PHLT, Biermasz NR, Pereira AM, Fliers E, Drent ML, 2014 A long-term follow-up study of eighteen patients with thyrotrophin-secreting pituitary adenomas. Clin Endocrinol (Oxf) 80: 395–402.CrossRefGoogle Scholar
  11. 11.
    Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau J-L, 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J 2: 76–82.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ness-Abramof R, Ishay A, Harel G, et al, 2007 TSH-secreting pituitary adenomas: follow-up of 11 cases and review of the literature. Pituitary 10: 307–310.CrossRefPubMedGoogle Scholar
  13. 13.
    Kessler M, David R, Pawelczak M, Hanono A, Shah B, 2010 Thyrotropin-Secreting Pituitary Adenoma in an Adolescent Boy: Challenges in Management. Pediatrics 126: e474–478.CrossRefPubMedGoogle Scholar
  14. 14.
    Beck-Peccoz P, Persani L, 2002 Medical management of thyrotropin-secreting pituitary adenomas. Pituitary 5: 83–88.CrossRefPubMedGoogle Scholar
  15. 15.
    Chanson P, Weintraub BD, Harris AG, 1993 Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas: A Follow-up of 52 patients. Ann Intern Med 119: 236–240.CrossRefPubMedGoogle Scholar
  16. 16.
    Prieto-Tenreiro A, Díaz-Guardiola P, 2010 Long term treatment of a thyrotropin-secreting microadenoma with somatostatin analogues. Arq Bras Endocrinol Metab 54: 502–506.CrossRefGoogle Scholar
  17. 17.
    Kuhn JM, Arlot S, Lefebvre H, et al, 2000 Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 85: 1487–1491.CrossRefPubMedGoogle Scholar
  18. 18.
    Gatto F, Barbieri F, Gatti M, et al, 2012 Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. Clin Endocrinol (Oxf) 76: 407–414.CrossRefGoogle Scholar
  19. 19.
    Elston MS, Conaglen JV, 2010 Clinical and biochemical characteristics of patients with thyroid-stimulating hormone-secreting pituitary adenomas from one New Zealand centre. Intern Med J 40: 214–219.CrossRefPubMedGoogle Scholar
  20. 20.
    Koga T, Shin M, Saito N, 2010 Role of γ knife radiosurgery in neurosurgery: past and future perspectives. Neurol Med Chir (Tokyo) 50: 737–748.CrossRefGoogle Scholar
  21. 21.
    Ohki M, Sato K, Tuchiya D, et al, 1999 A case of TSH-secreting pituitary adenoma associated with an unruptured aneurysm: successful treatment by two-stage operation and gamma-knife. No To Shinkei 51: 895–899.PubMedGoogle Scholar
  22. 22.
    Kon YC, Loh KC, Tambyah JA, Lim LH, Marshall JC, 2001 Thyrotrophin (TSH)-secreting pituitary macroadenoma with cavernous sinus invasion. Singapore Med J 42: 433–437.PubMedGoogle Scholar
  23. 23.
    Clarke MJ, Erickson D, Castro MR, Atkinson JLD, 2008 Thyroid-stimulating hormone pituitary adenomas. J Neurosurg 109: 17–22.CrossRefPubMedGoogle Scholar
  24. 24.
    Kasliwal M, Gupta A, Sharma M, 2012 Single low dose adjuvant Gamma knife radiosurgery for thyrotropin secreting pituitary adenoma. Acta Neurochir 154: 665–666.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhao W, Ye H, Li Y, et al, 2012 Thyrotropin-secreting pituitary adenomas: diagnosis and management of patients from one Chinese center. Wien Klin Wochenschr 124: 678–684.CrossRefPubMedGoogle Scholar
  26. 26.
    Gatto F, Grasso LF, Nazzari E, et al, 2015 Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy? Pituitary 18: 583–591.CrossRefPubMedGoogle Scholar
  27. 27.
    Fliers E, van Furth WR, Bisschop PH, 2012 Cure of a thyrotrophin (TSH)-secreting pituitary adenoma by medical therapy. Clin Endocrinol (Oxf) 77: 788–790.CrossRefGoogle Scholar
  28. 28.
    Rabbiosi S, Peroni E, Tronconi GM, Chiumello G, Losa M, Weber G, 2012 Asymptomatic Thyrotropin-Secreting Pituitary Macroadenoma in a 13-Year-Old Girl: Successful First-Line Treatment with Somatostatin Analogs. Thyroid 22: 1076–1079.CrossRefPubMedGoogle Scholar
  29. 29.
    Minniti G, Clarke E, Scaringi C, Enrici RM, 2014 Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas. Rep Pract Oncol Radiother. Available at: http://www.sciencedirect.com/science/article/pii/S1507136714001497.
  30. 30.
    Mak HK-F, Lai S-W, Qian W, et al, 2014 Effective time window in reducing pituitary adenoma size by gamma knife radiosurgery. Pituitary 18: 509–517.CrossRefGoogle Scholar
  31. 31.
    Chen Y, Li ZF, Zhang FX, et al, 2013 Gamma knife surgery for patients with volumetric classification of nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Eur J Endocrinol 169: 487–495.CrossRefPubMedGoogle Scholar
  32. 32.
    Marek J, Ježková J, Hána V, et al, 2011 Is it possible to avoid hypopituitarism after irradiation of pituitary adenomas by the Leksell gamma knife? Eur J Endocrinol 164: 169–178.CrossRefPubMedGoogle Scholar
  33. 33.
    Leavitt JA, Stafford SL, Link MJ, Pollock BE, 2013 Long-term evaluation of radiation-induced optic neuropathy after single-fraction stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 87: 524–527.CrossRefPubMedGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2016

Authors and Affiliations

  • Zadalla Mouslech
    • 1
  • Maria Somali
    • 2
  • Anastasia Konstantina Sakali
    • 2
  • Christos Savopoulos
    • 1
  • George Mastorakos
    • 2
  • Apostolos I. Hatzitolios
    • 1
  1. 1.1st Medical Propedeutic Dept of Internal Medicine, AHEPA University HospitalAristotle University of ThessalonikiThessalonikiGreece
  2. 2.Department of Endocrinology, Metabolism and Diabetes, Aretaieio Hospital, School of MedicineUniversity of AthensAthensGreece

Personalised recommendations